Expert opinion on drug delivery最新文献_第4页

Bacterial and bacterial derivatives-based drug delivery systems: a novel approach for treating central nervous system disorders. 基于细菌和细菌衍生物的药物传递系统：治疗中枢神经系统疾病的新方法。

Expert opinion on drug delivery Pub Date : 2024-12-22 DOI: 10.1080/17425247.2024.2444364

Shizhu Gao, Xin Li, Bing Han

{"title":"Bacterial and bacterial derivatives-based drug delivery systems: a novel approach for treating central nervous system disorders.","authors":"Shizhu Gao, Xin Li, Bing Han","doi":"10.1080/17425247.2024.2444364","DOIUrl":"10.1080/17425247.2024.2444364","url":null,"abstract":"Introduction: Bacteria and their derivatives show great potential as drug delivery systems due to their unique chemotaxis, biocompatibility, and targeting abilities. In CNS disease treatment, bacterial carriers can cross the blood-brain barrier (BBB) and deliver drugs precisely, overcoming limitations of traditional methods. Advances in genetic engineering, synthetic biology, and nanotechnology have transformed these systems into multifunctional platforms for personalized CNS treatment.Areas covered: This review examines the latest research on bacterial carriers for treating ischemic brain injury, neurodegenerative diseases, and gliomas. Bacteria efficiently cross the blood-brain barrier via active targeting, endocytosis, paracellular transport, and the nose-to-brain route for precise drug delivery. Various bacterial drug delivery systems, such as OMVs and bacterial ghosts, are explored for their design and application. Databases were searched in Google Scholar for the period up to December 2024.Expert opinion: Future developments in bacterial drug delivery will rely on AI-driven design and high-throughput engineering, enhancing treatment precision. Personalized medicine will further optimize bacterial carriers for individual patients, but challenges such as biosafety, immune rejection, and scalability must be addressed. As multimodal diagnostic and therapeutic strategies advance, bacterial carriers are expected to play a central role in CNS disease treatment, offering novel precision medicine solutions.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1-18"},"PeriodicalIF":0.0,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanomedicines modulate the tumor immune microenvironment for cancer therapy. 纳米药物调节肿瘤免疫微环境以治疗癌症。

Expert opinion on drug delivery Pub Date : 2024-12-01 Epub Date: 2024-10-04 DOI: 10.1080/17425247.2024.2412245

Po-Han Chao, Vanessa Chan, Shyh-Dar Li

{"title":"Nanomedicines modulate the tumor immune microenvironment for cancer therapy.","authors":"Po-Han Chao, Vanessa Chan, Shyh-Dar Li","doi":"10.1080/17425247.2024.2412245","DOIUrl":"10.1080/17425247.2024.2412245","url":null,"abstract":"Introduction: In recent years, the evolution of immunotherapy as a means to trigger a robust antitumor immune response has revolutionized cancer treatment. Despite its potential, the effectiveness of cancer immunotherapy is hindered by low response rates and significant systemic side effects. Nanotechnology emerges as a promising frontier in shaping the future of cancer immunotherapy.Areas covered: This review elucidates the pivotal role of nanomedicine in reshaping the immune tumor microenvironment and explores innovative strategies pursued by diverse research groups to enhance the therapeutic efficacy of cancer immunotherapy. It discusses the hurdles encountered in cancer immunotherapy and the application of nanomedicine for small molecule immune modulators and nucleic acid therapeutics. It also highlights the advancements in DNA and mRNA vaccines facilitated by nanotechnology and outlines future trajectories in this evolving field.Expert opinion: Collectively, the integration of nanomedicine into cancer immunotherapy stands as a promising avenue to tackle the intricacies of the immune tumor microenvironment. Innovations such as immune checkpoint inhibitors and cancer vaccines have shown promise. Future developments will likely optimize nanoparticle design through artificial intelligence and create biocompatible, multifunctional nanoparticles, promising more effective, personalized, and durable cancer treatments, potentially transforming the field in the foreseeable future.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1719-1733"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential of nanosystems in disrupting adenosine signaling pathways for tumor immunotherapy. 纳米系统在破坏腺苷信号通路促进肿瘤免疫疗法方面的潜力。

Expert opinion on drug delivery Pub Date : 2024-12-01 Epub Date: 2024-11-21 DOI: 10.1080/17425247.2024.2417687

Yutong Zhao, Jingqi Sun, Xiao-Ling Xu, Jin Su, Yong-Zhong Du

引用次数: 0

Future clinical potential of leukocyte-mimicking nanoparticles. 仿白细胞纳米粒子的未来临床潜力。

Expert opinion on drug delivery Pub Date : 2024-12-01 Epub Date: 2024-11-17 DOI: 10.1080/17425247.2024.2430389

Francesca Taraballi

引用次数: 0

An opinion on advanced cancer immunotherapy through innovations in PD-1 inhibitor delivery systems. 通过 PD-1 抑制剂给药系统的创新实现先进的癌症免疫疗法。

Expert opinion on drug delivery Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1080/17425247.2024.2428623

Piyush Kumar Gupta, Harshita Tiwari, Richa Mishra, Kalpana Balakrishnan, Shikha Singh, Sandeep Kumar, Kavindra Kumar Kesari, Saravanan Krishnan

引用次数: 0

Ocular delivery of Amphotericin B: current challenges and future perspectives. 两性霉素 B 的眼部给药：当前挑战与未来展望。

Expert opinion on drug delivery Pub Date : 2024-12-01 Epub Date: 2024-10-27 DOI: 10.1080/17425247.2024.2420750

Velmurugan Kailasam, Samhita Sai Veda Koduganti, Oindrilla Dasgupta, Prashant Garg, Jayabalan Nirmal

{"title":"Ocular delivery of Amphotericin B: current challenges and future perspectives.","authors":"Velmurugan Kailasam, Samhita Sai Veda Koduganti, Oindrilla Dasgupta, Prashant Garg, Jayabalan Nirmal","doi":"10.1080/17425247.2024.2420750","DOIUrl":"10.1080/17425247.2024.2420750","url":null,"abstract":"Introduction: Amphotericin B is a polyene antibiotic that is used as an off-label eye drop to treat fungal keratitis. Poor solubility, permeability and high susceptibility to hydrolytic degradation make it challenging to formulate a drug delivery system. Despite its drawbacks, it is a potent antifungal drug against Candida and other fungal species. However, it has not been explored much in ocular drug delivery. Hence, this review brings into focus the potential and increasing significance of Amphotericin B in ocular drug delivery.Areas covered: In this review, we have systematically summarized the use of Amphotericin B in ocular diseases, the various formulation challenges for Amphotericin B, along with its off-label ocular usage, and stability concerns. The degradation mechanism of Amphotericin B in different conditions was discussed in this article as well.Expert opinion: In the last few decades, several nanocarriers have been explored to improve the formulation challenges associated with Amphotericin B. Also, due to insufficient clinical studies and unknown toxicity profile, there is no US Food and Drug Administration (FDA) approved Amphotericin B formulation for ocular drug delivery. This review aims to offer thorough information about Amphotericin B in ocular drug delivery.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1793-1805"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acceptability of Cyltezo pen among biologics autoinjector patients, autoinjector naïve patients, and healthcare professionals. 生物制剂自动注射器患者、自动注射器新手患者和医护人员对 CYLTEZO 笔的接受程度。

Expert opinion on drug delivery Pub Date : 2024-12-01 Epub Date: 2024-11-21 DOI: 10.1080/17425247.2024.2394112

Raul Perez, Julie D Suman, Joe Reynolds

{"title":"Acceptability of Cyltezo pen among biologics autoinjector patients, autoinjector naïve patients, and healthcare professionals.","authors":"Raul Perez, Julie D Suman, Joe Reynolds","doi":"10.1080/17425247.2024.2394112","DOIUrl":"10.1080/17425247.2024.2394112","url":null,"abstract":"Background: Cyltezo® (Adalimumab-adbm) is an FDA-approved interchangeable biosimilar for Humira® (adalimumab reference product [RP]) that helps treat chronic inflammatory conditions. Adalimumab-adbm is administered via an autoinjector, the adalimumab-adbm pen. This study assessed user opinions related to usability, perceptions, convenience, safety features, and acceptability of the adalimumab-adbm pen.Methods: Ninety-eight Humira Pen users, 100 biologics pen naïve patients, and 99 healthcare professionals simulated the use of the adalimumab-adbm pen on injection pads. Opinions were captured with a validated questionnaire using Likert-type scales during moderated interviews. Binomial tests were conducted for top-two rating percentages.Results: Nearly 90% of participants found the adalimumab-adbm pen 'easy' or 'very easy' to use, handle, and learn how to use. Almost 90% of volunteers thought the pen was 'very' or 'extremely' solid and convenient to use at home. Around 80% found the pen to be 'very' or 'extremely' comfortable. Over 90% of respondents said they would be 'satisfied' or 'very satisfied' with the safety features and the device itself. Nearly 90% of respondents indicated being 'very' or 'extremely' open to adopting the adalimumab-adbm pen.Conclusions: The adalimumab-adbm pen provided users with a positive experience with features that benefit perceptions of usability, handling, safety, convenience, and acceptability.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1879-1888"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of microneedle applicators for vaccination: the role of the latch applicator in optimizing dissolving microneedle-based immunization. 用于疫苗接种的微针涂抹器的演变：闩式涂抹器在优化基于溶解微针的免疫接种中的作用。

Expert opinion on drug delivery Pub Date : 2024-12-01 Epub Date: 2024-10-30 DOI: 10.1080/17425247.2024.2422939

Minkyung Kim, Geonwoo Kang, Hye Su Min, Youjin Lee, Shinyoung Park, Hyungil Jung

{"title":"Evolution of microneedle applicators for vaccination: the role of the latch applicator in optimizing dissolving microneedle-based immunization.","authors":"Minkyung Kim, Geonwoo Kang, Hye Su Min, Youjin Lee, Shinyoung Park, Hyungil Jung","doi":"10.1080/17425247.2024.2422939","DOIUrl":"10.1080/17425247.2024.2422939","url":null,"abstract":"Introduction: Dissolving microneedles (DMN) offer advantages in vaccine delivery, such as enhanced immunogenicity and simplified administration, by targeting immune-rich layers of the skin. However, these benefits require precise and consistent delivery, which poses practical challenges. To address this, specialized applicators are essential for ensuring the accurate deployment of DMNs, making this technology a viable alternative to traditional methods, particularly in low- and middle-income countries (LMICs), where healthcare infrastructure is limited.Areas covered: In this review, we examine the advancements in DMN-based vaccination and applicator design, focusing on their joint effort. These innovations have improved the precision and efficiency of DMN vaccine delivery. Complex and costly early-stage applicators have evolved into simpler and more cost-effective designs. We highlight these developments in this review, with the latch applicator as a key example of a feature that enhances vaccine delivery.Expert opinion: Although applicator development has advanced DMN-based vaccination toward practical use, challenges remain. Key areas for further optimization include user friendliness, cost, packaging volume, and wear time. Once optimized, DMN vaccination may become a highly effective and accessible tool for global immunization, supporting efforts to achieve worldwide vaccine equality.","PeriodicalId":94004,"journal":{"name":"Expert opinion on drug delivery","volume":" ","pages":"1823-1835"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142515257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suprachoroidal drug delivery: a versatile therapeutic platform. 脉络膜上给药：一个多功能的治疗平台。

Expert opinion on drug delivery Pub Date : 2024-12-01 Epub Date: 2024-12-06 DOI: 10.1080/17425247.2024.2435461

Thomas A Ciulla, Emmett T Cunningham

引用次数: 0

Are membrane-interacting peptides viable as excipients for non-injectable peptide delivery? 膜相互作用肽是否可以作为非注射肽递送的辅料？

Expert opinion on drug delivery Pub Date : 2024-12-01 Epub Date: 2024-12-08 DOI: 10.1080/17425247.2024.2435455

Hanne Mørck Nielsen

引用次数: 0